Advertisement

Topics

Latest "BioTech Capital Limited" News Stories

03:22 EST 14th December 2017 | BioPortfolio

Here are the most relevant search results for "BioTech Capital Limited" found in our extensive news archives from over 250 global news sources.

More Information about BioTech Capital Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioTech Capital Limited for you to read. Along with our medical data and news we also list BioTech Capital Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioTech Capital Limited Companies for you to search.

Showing "BioTech Capital Limited" News Articles 1–25 of 10,000+

Relevant

Where is the Money Going in Biotech? A Peek into European VC Strategy

Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, ... This awesome article Where is the Money Going in Biotech? A Peek into European VC Strategy appeared first on Labiotech.eu. Be kind and do...


Will Biotech Continue To Boom?

Biotechs have surged in 2017 - how much higher can they fly?Avisol Capital Partners joins the Roundtable to discuss their approach to biotech valuations and the warning signs they look for in the stocks they research.They also opine on Celyad and CAR-T, and the near-term future of the biotech sector as a whole.

eG Capital: Australian Biotech: A 2007 Perspective from Alison Coutts

In this exclusive interview, Fintan Walton talks to Alison Coutts, Executive Director at eG Capital in Sydney, Australia. Alison reviews some of the major changes she has observed in the biotech and pharmaceutical industry in Australia over the last 12 months, reflecting on the progress that many companies have made and the general maturation of the industry as a whole. She discusses the increasin...


Aisling Capital: Investment Strategies and How to Revive Biotech

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dennis Purcell at Aisling Capital. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss: • Dennis' history in the biotech sector • Key changes to biotech business models in the last 30 years • Aisling's investment strategy • How the company raised US $650M in January 2009, and how that fund is being ...

Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights 04-Dec-2017 / 08:45 CET/CEST Dissemination of a...

MPM Capital: The Perfect Storm in Healthcare

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Vaughn Kailian, Managing Director at MPM Capital, one of the world's largest life science-dedicated venture investors. They discuss: • why 2009 has been a landmark year for the biotech industry • survival in the current financial crisis • healthcare reform and the politcs involved • how the best ideas wil...

Beck Capital Management LLC Boosts Stake in SPDR S&P Biotech Etf

Beck Capital Management LLC grew its stake in shares of SPDR S&P Biotech ETF by 235.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,899 shares of the exchange traded fund's stock after acquiring an additional 44,866 shares during the period.

STAT Plus: We need to discard the ratty T-shirts of biotech. Anyone up for a Venture Capital Death Panel?

Too many biotech companies are old, tired, and have no realistic hope of developing new drugs. We need to cull them to make room for new prospects.

TVM Capital: Investment Strategies, Relationships with Big Pharma and Biotech Financing

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dr Axel Polack, General Partner at TVM Capital. Filmed at BioBusiness 2010 in London, England, they discuss: • TVM’s investment strategy • Platform companies • The effects of the economic crisis • Milestones, exit strategies and the lack of an IPO market • Relationships with big Pharma • Financing in the biotec...

Financial Partners Capital Management LLC Has $6.02 Million Position in SPDR S&P Biotech Etf

Financial Partners Capital Management LLC lowered its stake in shares of SPDR S&P Biotech ETF by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 69,566 shares of the exchange traded fund's stock after selling 2,025 shares during the quarter.

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

FIT Biotech Oy Company release October 5, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's board of directors have  resolved on October 4, ...

3 Biotech Stocks to Buy Now for Gains Up to 93%

Finding the best biotech stocks to buy now can be exhausting, especially when investors have to read pages of technical jargon to find out what each company does. We've put together a list of the three best biotech stocks to buy right now, including our top biotech stock pick, one with the potential for 93% growth in a year These biotech stocks are each benefiting from new drugs hitting the ma...

Meet the Experts: Discussion on Early-Stage Financing of Biotech Companies in Europe

Fintan Walton leads our panel of industry experts in an in-depth discussion about the early-stage financing of biotech companies in Europe. With viewpoints from both financial and biotech companies, our panellists provide a refreshing perspective on the current issues that face would-be CEOs, trying to secure seed capital in Europe's biotech start-up arena.

Aisling Capital Closes $280M Fund to Improve Global Health

NewsAisling Capital will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization.

Paul Capital Partners: Growth Capital Providers for the Biotech Industry

In this interview, filmed during the recent BIO conference in San Diego, Fintan Walton speaks with Ken Macleod, partner in the well-known Paul Capital Partners, located in London. He tells how the company differs from traditional venture capitalist funds by providing funding based on royalty interests and revenue interests. Using these methods, Paul Capital is able to provide non-dilutive funding ...

Jacobson Pharma Completes Issue of HK$500 Million of Convertible Notes to Dragons 615 Limited and HH InRe JP, Ltd.

HONG KONG, CHINA -- (Marketwired) -- 10/03/17 -- Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group") (HKSE: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, is pleased to announce the completion of issue of the Convertible Notes in a principal amount of HK$500 million to two subscribers nam...

Laing Tapped to Lead New Capital City Innovation District in Austin

Austin—The Texas capital is already known as a hub for young innovative tech companies. Now, Austin is working on expanding its entrepreneurial portfolio with a new innovation zone targeting biotech. Austin leaders recently announced that Christopher Laing will be the first executive director of the Capital City Innovation District, a 14-acre zone in downtown Austin […]

Aisling Capital: How Funding Must Adapt to the Current Market

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Dennis Purcell, Senior Managing Partner at Aisling Capital, an investment company dedicated to funding global healthcare companies. They discuss: • Dennis' experiences of the market's booms and slumps • how funding has had to adapt • bankruptcies and efficiency of capital • how the funding model will chan...

Azura Ophthalmics closes $16mm Series B round

Azura Ophthalmics Ltd. raised $16mm in its Series B financing led by OrbiMed, TPG Biotech, and Brandon Capital, all of which ...

MorphoSys-Aktie: Shortseller Capital Fund Management nimmt MorphoSys erneut unter Beschuss! Aktiennews

Martinsried - Leerverkäufer Capital Fund Management SA baut Netto-Leerverkaufsposition in MorphoSys-Aktien erneut aus: Die Leerverkäufer von Capital Fund Management SA haben die Aktien des Biotech-...

New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer

Spin-out, NeoPhore, has received investment from Sixth Element Capital to develop small molecules that stimulate the immune system against cancer. Sixth Element Capital has invested £3M (€3.3M) in NeoPhore, a new spin-out from PhoreMost – a drug discovery company based in Cambridge, ... This awesome article New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer a...

Private equity firm invests in Cambridge biotech

A private equity firm, Calculus Capital, has invested £2.5 million in the Cambridge-based biotech company, Axol Bioscience.

Marinomed Biotech AG Raises 7 Million On Capital Market

  Life Sciences Jobs   ...

Conversion Of FIT Biotech's Convertible Capital Notes Into Shares

  Life Sciences Jobs   ...

Adial Pharmaceuticals sets terms for $14M IPO

Adial Pharmaceuticals, a biotech developing therapeutic treatments for alcohol use disorder has announced terms for its IPO. The Charlottesville, VA-based company plans to raise $14 million by offering 1.4 million shares at a price range of $9 to $11. At the midpoint of the proposed range, Adial Pharmaceuticals would command a fully diluted market value of $57 million. Adial Pharmaceuticals wa...


Quick Search
Advertisement
 

News Quicklinks